Ligand to Participate in June Investor Conferences
Ligand (Nasdaq: LGND) announced participation in two June 2026 investor conferences.
Rhea-AI Summary
Ligand (Nasdaq: LGND) announced participation in two June 2026 investor conferences. At the Stifel 2026 Boston Cross Sector 1x1 Conference, management will hold one-on-one investor meetings on June 3, 2026 in Boston.
At the Goldman Sachs 47th Annual Global Healthcare Conference, management will host a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami, followed by one-on-one meetings.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LGND
In the May 28 session, LGND declined 0.52%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Conference date
- June 3, 2026
- Stifel 2026 Boston Cross Sector 1x1 Conference
- Conference date
- June 10, 2026
- Goldman Sachs 47th Annual Global Healthcare Conference
- Conference time
- 10:00 a.m. ET
- Goldman Sachs fireside chat time
- Conference edition
- 47th
- Goldman Sachs Annual Global Healthcare Conference
- Current price
- $235.33
- Price before this conference news
- Price change 24h
- 2.62%
- Move on the session of publication
- 52-week range
- $98.89 – $247.38
- Low and high prior to this news
- Market cap
- $4,716,262,885
- Equity value before conferences announcement
Historical Context
-
Strong Q1 revenue, royalty growth and reaffirmed 2026 guidance.
-
Announcement of management participation in multiple May investor conferences.
-
Agreement to acquire XOMA Royalty, expanding royalty assets and raising guidance.
-
Scheduling of Q1 2026 earnings call and webcast details.
-
Partner Travere gained full FDA approval for FILSPARI with 9% royalty to Ligand.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:
- Stifel 2026 Boston Cross Sector 1x1 Conference. Management will participate in one-on-one meetings with investors on June 3, 2026 in Boston.
- Goldman Sachs 47th Annual Global Healthcare Conference. Management will participate in a fireside chat on June 10, 2026 at 10:00 a.m. ET in Miami followed by one-on-one meetings with investors.
Investors interested in arranging one-on-one meetings should contact their Stifel or Goldman Sachs representative.
About Ligand Pharmaceuticals
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.